Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0001264124-12-000107)

Filing Details

Accession Number:
0001264124-12-000107
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-03-29 20:17:10
Reporting Period:
2012-03-28
Filing Date:
2012-03-29
Accepted Time:
2012-03-29 19:17:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
881464 Amylin Pharmaceuticals Inc AMLN Pharmaceutical Preparations (2834) 330266089
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1236395 A Lloyd Rowland 9360 Towne Centre Dr
San Diego CA 92121		 Vp, Chief Compliance Officer No Yes No No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-03-28 5,000 $9.02 42,603 No 4 M Direct
Common Stock Disposition 2012-03-28 5,000 $22.83 37,603 No 4 S Direct
Common Stock Disposition 2012-03-29 3,000 $25.00 34,603 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Show Other Fields >>
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2012-03-28 5,000 $22.83 5,000 $9.02
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
18,750 2016-03-04 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 3,665 Indirect Indirect-401k
Common Stock 7,974 Indirect by ESOP
Footnotes
  1. The sale was affected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. 25% of shares vested one year from date of grant and the remainder vested monthly over the next three years becoming fully vested four years from date of grant.